Role of Biomarkers in Endometrial Cancer Recurrence in Samples From Patients With Stage II, Stage III, or Stage IV Endometrial Cancer
Endometrial Cancer
About this trial
This is an observational trial for Endometrial Cancer focused on measuring endometrial adenocarcinoma, stage II endometrial carcinoma, stage III endometrial carcinoma, stage IV endometrial carcinoma, endometrial adenosquamous cell carcinoma, endometrial clear cell carcinoma, endometrial papillary serous carcinoma
Eligibility Criteria
DISEASE CHARACTERISTICS:
Histologically confirmed endometrioid endometrial cancer
- Stage II-IV disease
Patients who were eligible and evaluated on the GOG-0210, Molecular Staging in Endometrial Cancer clinical trial, meeting the following criteria:
- Allowed their specimens and clinical data collected as part of their participation
- Have sufficient high-quality frozen primary tumor, formalin-fixed and paraffin-embedded (FFPE) primary tumor, and/or pre-operative serum for testing available
Patients who underwent surgical staging as specified in the GOG-0210 protocol and described in the GOG Surgical Manual Protocol, including any of the following procedures:
- Hysterectomy
- Bilateral oophorectomy
- Washings as well as pelvic lymphadenectomy and para-aortic lymphadenectomy
Non-cancerous endometrial tissue and fasting serum from control samples meeting the following criteria (controls):
- Underwent hysterectomy to treat uterine prolapse at the Albert Einstein Hospital and Montefiore Medical Center, in the Bronx, NY
- No uterine fibroids or prior cancer
PATIENT CHARACTERISTICS:
- Postmenopausal patients and controls
PRIOR CONCURRENT THERAPY:
- See Disease Characteristics